The U.S. Food & Drug Adminstration has issued a warning letter to Alkermes, Inc., the makers of Vivitrol, for failing to disclose the injectable drug's most serious risks in an advertisement. Vivitrol ...

WALTHAM, Mass.-- (BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced that the supplemental New Drug Application (sNDA) for VIVITROL ® (naltrexone for extended-release injectable suspension) ...

Stinging investigations by the New York Times, National Public Radio, ProPublica, and others have recently exposed how the drug maker Alkermes is promoting Vivitrol — a long-acting injection that ...

DUBLIN, Ireland, Nov. 9, 2011 – Alkermes plc (NASDAQ: ALKS) today presented positive results from a long-term study of VIVITROL® (naltrexone for extended-release injectable suspension) at the 24th ...

WALTHAM, Mass., April 27, 2011 – Alkermes, Inc. (NASDAQ: ALKS) today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in ...

WALTHAM, Mass., Sep 16, 2010 (BUSINESS WIRE) -- Alkermes, Inc. (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to ...

DENVER (CBS4) - There is now a Food and Drug Administration-approved, monthly injection to treat addiction to alcohol, heroin and prescription pain pills. It's called Vivitrol. They prescribe it at ...

U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the ...

First approved by the FDA for use to treat opioid addiction in 2002, buprenorphine-based medications are most often taken as pills or films that dissolve under the tongue or inside the cheek. Last ...